CMPI News and Press, Checkmate Pharmaceuticals Inc. From 04/19/22

What To Know About Buying Penny Stocks on April 19th With another day of buying penny stocks here, there is a lot for investors to know. During early morning trading, we saw gainers like Sharps Technology Inc. ( NASDAQ: STSS ) and Navidea Biopharmaceuticals Inc. ( NYSE: NAVB ) g...

Checkmate Pharmaceuticals (CMPI) +332% Regeneron to acquire Checkmate Pharma in $250 million all-cash deal. Axsome Therapeutics (AXSM) +27%. Super Micro Computer (SMCI) +16% on raised Q3 guidance. 4D pharma (LBPS) +13%. American Campus Communities (ACC) +13% Blac...

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types PR Newswire Proposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology can...

Checkmate Pharmaceuticals Inc. (NASDAQ:CMPI) traded today at a new 52-week high of $20.05. Approximately 1.4 million shares have changed hands today, as compared to an average 30-day volume of 9,000 shares. Checkmate Pharmaceuticals Inc. (NASDAQ:CMPI) is currently priced 2.1% above its a...

CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat...

Checkmate Pharmaceuticals press release (NASDAQ:CMPI): FY GAAP EPS of -$2.84. Cash, cash equivalents and available-for-sale investments were $70.9 million as of December 31, 2021. For further details see: Checkmate Pharmaceuticals GAAP EPS of -$2.84

Alan Bash, experienced biopharmaceutical executive, appointed President and CEO Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer indications ongoing; Trial dosing initiated in cohorts for PD-1 refractory non-melanoma skin cancers Prelimina...

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat...

Checkmate Pharmaceuticals (NASDAQ:CMPI) announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1, 2022. Bash, who will also join the board, will succeed Alan Fuhrman, who has served as interim President and Chief Executive Officer since October 2021. ...

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today a...